<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818333</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1811-I-103</org_study_id>
    <nct_id>NCT04818333</nct_id>
  </id_info>
  <brief_title>A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      and efficacy of SHR-A1811 for injection in subjects with advanced non-small cell lung cancer&#xD;
      who have HER2 expression , amplification, or mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm study of SHR-A1811</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811</measure>
    <time_frame>From Day 1 to90 days after last dose ，appropriately to 3 years</time_frame>
    <description>Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811</measure>
    <time_frame>From Day 1 to90 days after last dose ，appropriately to 3 years</time_frame>
    <description>Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase1: Maximum tolerated dose (MTD)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence rate and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A1811 treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>RP2D was determined based on the safety, tolerability, PK, immunogenicity data and efficacy information obtained</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase2:ObjectiveResponse Rate (ORR)</measure>
    <time_frame>Subjects were evaluated on tumor imaging every 6 weeks after treatment initiation and every 12 weeks after 54 weeks, until imaging progression, initiation of new antitumor therapy, loss of follow-up, and death，appropriately to 3 years</time_frame>
    <description>As assessed by RECIST v1.1 , as assessed by independent review committee (IRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1：PK parameter ：Tmax of SHRA1811</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>Time to maximal concentration (Tmax) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase1:PK parameter: Cmax of SHR-A1811</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>Maximal concentration (Cmax) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase1:PK parameter: AUC0-t of SHR-A1811</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>AUC computed from time zero to the time of the last quantifiable concentration (AUC0-t) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase1:Immunogenicity of SHR-A1811</measure>
    <time_frame>Immunogenicity sample collection time points include: within 30 min before administration of C1D1, C2D1, C3D1, C4D1, C6D1 and C8D1 starting from cycle 11 only in every 3 cycles ,appropriately to 3 years</time_frame>
    <description>Including anti-drug antibody and/or neutralizing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2:Progression Free Survival (PFS)</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2:ObjectiveResponse Rate (ORR)</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>As assessed by RECIST v1.1 , as assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2:Duration of response (DOR)</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2:Disease control rate (DCR)</measure>
    <time_frame>appropriately to 3 years</time_frame>
    <description>As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2:Overall survival (OS)</measure>
    <time_frame>Approximately 5 years after last subject enrolled</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-A1811</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811</intervention_name>
    <description>Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1</description>
    <arm_group_label>SHR-A1811</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          3. advanced non-small cell lung cancer with HER2 expression , amplification, or mutation&#xD;
&#xD;
          4. has previously received platinum-based chemotherapy for advanced or metastatic NSCLC,&#xD;
             has developed disease progression during or after treatment, or is unable to tolerate&#xD;
             platinum-based chemotherapy.&#xD;
&#xD;
          5. There is at least one measurable lesion according to RECIST V1.1 criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has unresolved toxicities from previous anticancer therapy, defined as toxicities not&#xD;
             yet resolved to NCI-CTCAE version 5.0 grade ≤ 1.&#xD;
&#xD;
          2. Has received HER2 antibody drug conjugates,&#xD;
&#xD;
          3. Central nervous system metastasis or meningeal metastasis with clinical symptoms&#xD;
&#xD;
          4. Has active infection requiring systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Shi, MD,PhD</last_name>
    <phone>+86 021-61053363</phone>
    <email>Shiwei@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xun Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

